Title
Philadelphia City Council calls on the Pennsylvania General Assembly to add medetomidine to the list of controlled substances list in Pennsylvania.
Body
WHEREAS, The City of Philadelphia continues to face an ongoing drug epidemic that threatens public health and safety. The Department of Public Health reported about 1,300 fatal overdoses in 2023, with early data suggesting a slight decline in 2024, though the rate remains among the highest in the nation; and
WHEREAS, Medetomidine is a veterinary sedative that produces deep sedation, analgesia, and muscle relaxation through activation of a-adrenergic receptors. It is licensed only for veterinary use and has not been approved for human application or consumption; and
WHEREAS, The Philadelphia Department of Public Health has reported the rapid emergence of medetomidine in the city's illicit drug supply. Beginning in mid-2024, medetomidine largely replaced xylazine as a common adulterant in fentanyl. By November 2024, approximately 87 percent of the illicit drug samples tested contained medetomidine; and
WHEREAS, Medetomidine is estimated to be 100 to 200 times stronger than xylazine and, like xylazine, does not respond to opioid receptors. As a result, while naloxone (Narcan) can reverse the opioid effects in a mixed overdose, it cannot reverse the deep sedation or slowed heart rate and breathing caused by medetomidine; and
WHEREAS, There are currently no rapid test strips available to detect medetomidine, and most toxicology panels do not include it, leaving patients, providers, and public-health agencies without real-time data. Medetomidine remains unscheduled under both Pennsylvania law and the federal Controlled Substances Act, making it easily accessible through veterinary suppliers and overseas chemical vendors; and
WHEREAS, Medetomidine is not currently scheduled as a controlled substance in Pennsylvania, making it difficult for public health and law enforcement agencies to track, regulate, or re...
Click here for full text